Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | MRGPRX4 | Q96LA9 | 9/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.47 |
| ▸ | BCL2 | P10415 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16273716 | 0.90 | TP53 (0.56) | TP53HTTMRGPRX4FOLH1ALDH1A1 | |
| SCHEMBL17616591 | 0.90 | TP53 (0.68) | TP53HTTMRGPRX4FOLH1ALDH1A1 | |
| SCHEMBL17616617 | 0.89 | MRGPRX4 (0.55) | TP53HTTMRGPRX4FOLH1ALDH1A1 | |
| SCHEMBL17616599 | 0.88 | TP53 (0.46) | TP53HTTMRGPRX4FOLH1ALDH1A1 | |
| SCHEMBL17616651 | 0.87 | MRGPRX4 (0.69) | TP53HTTMRGPRX4FOLH1ALDH1A1 | |
| SCHEMBL17804521 | 0.85 | MRGPRX4 (0.59) | TP53HTTMRGPRX4FOLH1ALDH1A1 | |
| SCHEMBL27877447 | 0.85 | MRGPRX4 (0.59) | TP53HTTMRGPRX4FOLH1ALDH1A1 | |
| SCHEMBL16273717 | 0.85 | MRGPRX4 (0.61) | TP53HTTMRGPRX4FOLH1ALDH1A1 | |
| SCHEMBL7540548 | 0.85 | MRGPRX4 (0.59) | TP53HTTMRGPRX4FOLH1ALDH1A1 | |
| SCHEMBL16273718 | 0.85 | TP53 (0.64) | TP53HTTMRGPRX4FOLH1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9675072-B2 | Tetrazolinone compound and application of same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-06-13 | — | — | US | disclosed |
| US-9512090-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-12-06 | — | — | US | disclosed |
| US-20160081340-A1 | TETRAZOLINONE COMPOUND AND APPLICATION OF SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160081340-A1 | TETRAZOLINONE COMPOUND AND APPLICATION OF SAME | CYP2E1, MT-CO2, CASP3 | TP53 3963/4885HTT 3209/4885MRGPRX4 2185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.